Home LiteratureArticle Details
PMID: 24010542 Published · ppublish English

High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.

Clinical genetics ·Vol. 85 ·No. 1 ·2014-07-18

Konstantopoulou I, Tsitlaidou M, Fostira F, Pertesi M, Stavropoulou A-V, Triantafyllidou O, Tsotra E, Tsiftsoglou A P, Tsionou C, Droufakou S, Dimitrakakis C, Fountzilas G, Yannoukakos D

Abstract

We have screened 473 breast/ovarian cancer patients with family history, aiming to define the prevalence and enrich the spectrum of BRCA1/2 pathogenic mutations occurring in the Greek population. An overall mutation prevalence of 32% was observed. Six BRCA1 recurrent/founder mutations dominate the observed spectrum (58.5% of all mutations found). These include three mutations in exon 20 and three large genomic deletions. Of the 44 different deleterious mutations found in both genes, 16 are novel and reported here for the first time. Correlation with available histopathology data showed that 80% of BRCA1 carriers presented a triple-negative breast cancer phenotype while 82% of BRCA2 carriers had oestrogen receptor positive tumours. This study provides a comprehensive view of the frequency, type and distribution of BRCA1/2 mutations in the Greek population as well as an insight of the screening strategy of choice for patients of Greek origin. We conclude that the Greek population has a diverse mutation spectrum influenced by strong founder effects.

Keywords
BRCA1 BRCA2 Greece breast cancer germline mutation ovarian cancer
Article Info
Journal
Clinical genetics
Abbr.
Clin Genet
Published
2014-07-18
Indexed
2013-12-16
Updated
2014-09-19
Language
English
Country/Region
Denmark
NLM ID
0253664
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com